Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.

Daniel Castellano, Craig Gedye, Giuseppe Fornarini, Andre P. Fay, Jens Voortman, Michal Mego, Aristotelis Bamias, Jason Francis Lester, Robert A. Huddart, Michaela Matouskova, Howard Gurney, Begona Mellado, Michael Ong, Filipa Carneiro, Florian Seseke, Laura Milesi, Shahrokh F. Shariat, Simon Fear, Sabine de Ducla, Cora N. Sternberg

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of clinical oncology
Volume38
Issue number15
Publication statusPublished - 20 May 2020

Cite this